


Selected Innovative Medicines in Development as of January 21, 2026



Oncology (1 of 3)

AKEEGA (niraparib/abiraterone)
M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)

IMBRUVICA (ibrutinib)
Frontline Mantle Cell Lymphoma (Triangle)

RYBREVANT (amivantamab)
Subcutaneous (PALOMA-3)

CARVYKTI (Ciltacabtagene autoleucel)
Frontline Multiple Myeloma TNI (CARTITUDE-5)

ERLEADA (apalutamide)
High Risk Prostate Cancer (PROTEUS)

JNJ-1900 (NBTXR3)
Head and Neck Cancer

RYBREVANT (amivantamab)
Colorectal Cancer 2L (ORIGAMI-3)

TALVEY (talquetamab)
Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)

DARZALEX (daratumumab)
Smoldering Multiple Myeloma (AQUILA)

INLEXZO (gemcitabine intravesical delivery system)
Non Muscle Invasive Bladder Cancer (SunRISe-1)

TECVAYLI (teclistamab)
Multiple Myeloma 1-3PLs (MajesTEC-3)

CARVYKTI (Ciltacabtagene autoleucel)
Frontline Multiple Myeloma Transplant Eligible vs ASCT (CARTITUDE-6)

INLEXZO (gemcitabine intravesical delivery system)
Non Muscle Invasive Bladder Cancer BCG-naïve High Risk (SunRISe-3)

pasritamig
Prostate Cancer

RYBREVANT (amivantamab)
Head and Neck Cancer (ORIGAMI-5)

TALVEY (talquetamab)
Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

DARZALEX (daratumumab)
Frontline multiple myeloma transplant ineligible (CEPHEUS)

RYBREVANT (amivantamab)
Frontline Non Small Cell Lung Cancer in combination with chemotherapy (PAPILLON)

Bleximenib
Newly Diagnosed AML, chemo ineligible in combination with Venetoclax and Azacitidine (cAMeLot-2)

ERLEADA (apalutamide)
Localized Prostate Cancer (ATLAS)

INLEXZO (gemcitabine intravesical delivery system)
High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5)

RYBREVANT (amivantamab)
Colorectal Cancer (ORIGAMI-2)

TALVEY + TECVAYLI
Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6)

TALVEY (talquetamab)
TIE NDMM in combination with DR (MajesTEC-7)

TAR-210 (erdafitinib intravesical delivery system)
Non Muscle Invasive Bladder Cancer (MoonRISe-1)

TECVAYLI (teclistamab)
TIE NDMM in combination with DR (MajesTEC-7)

JNJ-0683 (ARX788)
Breast Cancer

JNJ-0387
Solid Tumors

JNJ-2638
Gastrointestinal Cancer

JNJ-4496
Hematological Malignancies

JNJ-4916
Lung Cancer

JNJ-8177 (ARX517)
Prostate Cancer

TAR-210 (erdafitinib intravesical delivery system)
High Risk Non Muscle Invasive Bladder Cancer (MoonRISe-3)

TECVAYLI (teclistamab)
Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9)

JNJ-1900 (NBTXR3)
Lung Cancer

JNJ-1493
Hematological Malignancies

JNJ-2761
Multiple Myeloma

JNJ-4680
Lung Cancer

JNJ-5322
Multiple Myeloma

JNJ-8377
Lymphoma

TECVAYLI (teclistamab)
TE NDMM maintenance (MajesTEC-4)

bleximenib
Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1)

TALVEY + TECVAYLI
Relapsed Refractory Multiple Myeloma (RedirectT-1)

JNJ-2175
Solid Tumors

JNJ-3413
Lymphoma

JNJ-4681
Hematological Malignancies

JNJ-7446
Lung Cancer

JNJ-8543
Hematological Malignancies

JNJ-9401
Prostate Cancer

JNJ-9968
Hematological Malignancies

JNJ-9530
Hematological Malignancies

JNJ-9892
Hematological Malignancies

Immunology (1 of 2)

icotrokinra Psoriasis (ICONIC)	SIMPONI (golimumab) Pediatric Ulcerative Colitis (PURSUIT 2)	STELARA (ustekinumab) Pediatric Crohn's Disease (UNITI JR)
STELARA (ustekinumab) Pediatric Ulcerative Colitis (UNIFI JR)	STELARA (ustekinumab) Pediatric Juvenile Psoriatic Arthritis	TREMFYA (guselkumab) Pediatric Psoriasis (PROTOSTAR)
TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)	TREMFYA (guselkumab) Ulcerative Colitis Subcutaneous Induction (ASTRO)	TREMFYA (guselkumab) Pediatric Juvenile Psoriatic Arthritis
icotrokinra Ulcerative Colitis (ICONIC-UC)	icotrokinra Psoriatic Arthritis (ICONIC-PsA)	nipocalimab Warm Autoimmune Hemolytic Anemia (ENERGY)
nipocalimab Sjogren's Disease	nipocalimab Hemolytic Disease of the Fetus and Newborn (AZALEA)	nipocalimab Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA)
TREMFYA (guselkumab) Pediatric Crohn's Disease (MACARONI-23)	TREMFYA (guselkumab) Pediatric Ulcerative Colitis (QUASAR JR)	icotrokinra Crohn's Disease (ICONIC-CD)
JNJ-4804 Co-antibody Therapy Ulcerative Colitis	JNJ-4804 Co-antibody Therapy Psoriatic Arthritis	JNJ-4804 Co-antibody Therapy Crohn's Disease
JNJ-5939 Atopic Dermatitis	nipocalimab Systemic Lupus Erythematosus	nipocalimab Idiopathic Inflammatory Myopathy

JNJ-5108
Immunological Diseases

JNJ-8638
Immunological Diseases

JNJ-6848
Immunological Diseases

JNJ-7528
Atopic Dermatitis

CAPLYTA (lumateperone)
Adjunctive Treatment for Major Depressive Disorder

CAPLYTA (lumateperone)
Bipolar Mania

RPGR Gene Therapy
Retinitis Pigmentosa (LUMEOS)

ITI-1284
Alzheimer's Disease-Related Psychosis

JNJ-2056 (tau active immunotherapy) *
Alzheimer's Disease (RETAIN)

IMAAVY (nipocalimab)
Generalized Myasthenia Gravis (Vivacity MG3)

CAPLYTA (lumateperone)
Pediatric Psychiatric Indications

seltorexant
Adjunctive Treatment for Major Depressive Disorder with
Insomnia Symptoms (OARS)

ITI-1284
Alzheimer's Disease-Related Agitation

JNJ-5120
Major Depressive Disorder

IMAAVY (nipocalimab)
Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG)

nipocalimab
Chronic Inflammatory Demyelinating Polyneuropathy
(ARISE)

ITI-1284
Generalized Anxiety Disorder

JNJ-1887 sCD59
Geographic Atrophy

SPRAVATO (esketamine)
Major Depressive Disorder with Suicidal Ideation
Pediatrics

Select Other Areas

CABENUVA

HIV Adolescents

milvexian (Factor Xla)

Secondary Stroke Prevention

SIRTURO

Tuberculosis Long Acting

UPTRAVI (selexipag)

Pediatric Pulmonary Arterial Hypertension (SALTO)

milvexian (Factor Xla)

Atrial Fibrillation

macitentan

Pulmonary Arterial Hypertension 75mg (UNISUS)

SIRTURO

Leprosy

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of January 21, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. *AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements -milvexian: Bristol Myers Squibb; AAV-RPGR: UCL Business Plc; JNJ-1887: Hemera Biosciences; Long acting HIV injectible treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; REMICADE and SIMPONI/SIMPONIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113: Protagonist Therapeutics; Tau Immunotherapy: AC Immune SA; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; DARZALEX and DARZALEX FASPRO: Genmab A/S; ERLEADA: Regents of California and Memorial Sloan Kettering; CARVYKT1: Legend Biotech; AKEEGA: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); CD20-directed autologous CAR-Ts: Cellular Biomedicine Group, Inc. (CBMG); muscarinic M1 receptor antagonist: Pipeline Therapeutics; NBTXR3: Nanobiotix; A2a Receptor Antagonist: AdoRx Therapeutics Limited